| No Details, But AstraZeneca Touts PARP Drug Win in Pancreatic Cancer | Ben Fidler | 02/26/19 | New York |
| With New Results, FibroGen’s Anemia Pill Inches Closer to FDA Review | Ben Fidler | 12/20/18 | San Francisco |
| FDA Halts Clinical Test of Zafgen Diabetes Drug, Stock Price Tumbles | Frank Vinluan | 11/26/18 | Boston |
| Illumina Set to Acquire “Long-Read” DNA Sequencer PacBio for $1.2B | Frank Vinluan | 11/01/18 | San Diego |
| Report: Express Scripts Shuts Out Teva Migraine Drug, Prefers Rivals | Frank Vinluan | 10/17/18 | National |
| FDA, Following EMA, Nixes Amicus’ Plans for Speedy OK of Pompe Drug | Ben Fidler | 09/10/18 | New York |
| Precision Bio Lands $110M as Gene-Edited Cell Therapy Nears Clinic | Frank Vinluan | 06/27/18 | Raleigh Durham |
| Exact Sciences, Mayo Clinic Share Data on DNA-Based Liver Cancer Test | Jeff Buchanan | 06/06/18 | Wisconsin |
| Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines | Frank Vinluan | 05/17/18 | National |
| Verdine Picks Backers For FogPharma’s $66M Round, Keeping Firm Control | Ben Fidler | 05/16/18 | Boston |
| Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms | Frank Vinluan | 04/19/18 | Indiana |
| Fresh Off $25M Raise, Generation Adds $100M For Next-Gen Gene Therapy | Ben Fidler | 02/27/18 | Boston |
| Aimmune’s Peanut Allergy Drug Hits Study Goals, FDA Filing Planned | Frank Vinluan | 02/20/18 | San Francisco |
| Avrobio Raises $60M for Fabry Disease Gene Therapy, Rest of Pipeline | Frank Vinluan | 02/01/18 | Boston |
| In Week of Hemophilia News, Alnylam Drug Cleared to Move Forward | Ben Fidler | 12/15/17 | Boston |
| Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another | Frank Vinluan | 11/20/17 | New York |
| Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study | Ben Fidler | 11/15/17 | New York |
| Sage Bounces Back, Eyes FDA Filing for Postpartum Drug | Ben Fidler | 11/09/17 | Boston |
| Five Prime Shares Dive on Latest Hiccup For Cancer Immunotherapy Combos | Frank Vinluan | 11/07/17 | San Francisco |
| Leerink’s Cozzens on New Health IT Fund, A.I.’s Future as a Platform | Jeff Bauter Engel | 10/20/17 | Boston |
| Boston Tech Watch: Leerink, E14 Fund, Jobcase, Freight Farms & More | Jeff Bauter Engel | 09/29/17 | Boston |
| Ultragenyx Makes Competing Bid for Gene Therapy Biotech Dimension Tx | Frank Vinluan | 09/18/17 | San Francisco |
| Amicus’s Scioderm Deal Flops as Skin Drug Fails in Phase 3 | Ben Fidler | 09/13/17 | New York |
| All Eyes on Depression Trials as Sage Neuro Drug Flunks Epilepsy Test | Ben Fidler | 09/12/17 | Boston |
| Novo Nordisk Diabetes Drug Beats Lilly’s Trulicity in Head-to-Head Test | Frank Vinluan | 08/17/17 | Indiana |
| Immunotherapy Shakeup: AstraZeneca Inks Merck Deal as Drug Combo Fails | Ben Fidler | 07/27/17 | National |
| Biogen, Opening Bottlenecks, Sees Spine Drug Sales, Shares Rise | Ben Fidler | 07/25/17 | Boston |
| Celgene’s Data Could Lead To New Option For Multiple Sclerosis Patients | Frank Vinluan | 05/22/17 | New York |
| FDA Wants More Safety Info on Psych Drug, Intra-Cellular Shares Drop | Ben Fidler | 05/01/17 | New York |
| Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug? | Ben Fidler | 04/26/17 | Boston |
